GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Accolade Inc (NAS:ACCD) » Definitions » Beneish M-Score

Accolade (Accolade) Beneish M-Score : -2.91 (As of May. 15, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Accolade Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.91 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Accolade's Beneish M-Score or its related term are showing as below:

ACCD' s Beneish M-Score Range Over the Past 10 Years
Min: -3.36   Med: 0.38   Max: 7.53
Current: -2.91

During the past 7 years, the highest Beneish M-Score of Accolade was 7.53. The lowest was -3.36. And the median was 0.38.


Accolade Beneish M-Score Historical Data

The historical data trend for Accolade's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accolade Beneish M-Score Chart

Accolade Annual Data
Trend Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24
Beneish M-Score
Get a 7-Day Free Trial - 3.67 7.53 -3.36 -2.91

Accolade Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.36 -3.20 -3.18 -2.97 -2.91

Competitive Comparison of Accolade's Beneish M-Score

For the Health Information Services subindustry, Accolade's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accolade's Beneish M-Score Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Accolade's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Accolade's Beneish M-Score falls into.



Accolade Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Accolade for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9096+0.528 * 0.9756+0.404 * 1.0596+0.892 * 1.1409+0.115 * 1.0493
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.7884+4.679 * -0.118717-0.327 * 0.9147
=-2.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Feb24) TTM:Last Year (Feb23) TTM:
Total Receivables was $27.7 Mil.
Revenue was 124.831 + 99.371 + 96.864 + 93.226 = $414.3 Mil.
Gross Profit was 66.637 + 44.853 + 41.547 + 39.023 = $192.1 Mil.
Total Current Assets was $284.9 Mil.
Total Assets was $788.2 Mil.
Property, Plant and Equipment(Net PPE) was $47.5 Mil.
Depreciation, Depletion and Amortization(DDA) was $45.2 Mil.
Selling, General, & Admin. Expense(SGA) was $162.2 Mil.
Total Current Liabilities was $107.9 Mil.
Long-Term Debt & Capital Lease Obligation was $234.6 Mil.
Net Income was -7.507 + -21.064 + -32.825 + -38.409 = $-99.8 Mil.
Non Operating Income was -0.493 + 9.281 + 0.753 + 0.39 = $9.9 Mil.
Cash Flow from Operations was 5.951 + 5.205 + -8.038 + -19.287 = $-16.2 Mil.
Total Receivables was $26.7 Mil.
Revenue was 99.025 + 90.946 + 87.643 + 85.528 = $363.1 Mil.
Gross Profit was 47.977 + 40.534 + 37.813 + 37.913 = $164.2 Mil.
Total Current Assets was $365.9 Mil.
Total Assets was $903.1 Mil.
Property, Plant and Equipment(Net PPE) was $44.3 Mil.
Depreciation, Depletion and Amortization(DDA) was $46.4 Mil.
Selling, General, & Admin. Expense(SGA) was $180.3 Mil.
Total Current Liabilities was $119.4 Mil.
Long-Term Debt & Capital Lease Obligation was $309.5 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(27.702 / 414.292) / (26.695 / 363.142)
=0.066866 / 0.073511
=0.9096

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(164.237 / 363.142) / (192.06 / 414.292)
=0.452267 / 0.463586
=0.9756

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (284.912 + 47.48) / 788.151) / (1 - (365.949 + 44.288) / 903.069)
=0.578264 / 0.54573
=1.0596

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=414.292 / 363.142
=1.1409

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(46.377 / (46.377 + 44.288)) / (45.164 / (45.164 + 47.48))
=0.51152 / 0.487501
=1.0493

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(162.19 / 414.292) / (180.322 / 363.142)
=0.391487 / 0.496561
=0.7884

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((234.559 + 107.85) / 788.151) / ((309.512 + 119.414) / 903.069)
=0.434446 / 0.474965
=0.9147

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-99.805 - 9.931 - -16.169) / 788.151
=-0.118717

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Accolade has a M-score of -2.91 suggests that the company is unlikely to be a manipulator.


Accolade Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Accolade's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Accolade (Accolade) Business Description

Traded in Other Exchanges
Address
1201 Third Avenue, Suite 1700, Seattle, WA, USA, 98101
Accolade Inc offers technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits. It generates revenue by providing personalized health guidance solutions to members.
Executives
Richard Eskew officer: EVP General Counsel C/O ACCOLADE, INC., 660 WEST GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462
Stephen H. Barnes officer: Chief Financial Officer C/O ACCOLADE, INC., 660 WEST GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462
Rajeev Singh director, officer: Chief Executive Officer 6222 185TH AVENUE NE, REDMOND WA 98052
Robert N Cavanaugh officer: President 1601 CLOVERFIELD BLVD., SUITE 620, SANTA MONICA CA 90404
Mchugh Colin officer: Chief Accounting Officer C/O ACCOLADE, INC., 660 W. GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462
Michael W Hilton officer: Chief Product Officer 6222 185TH AVE, REDMOND WA 98052
Peter S Klein director C/O MICROSOFT CORPORATION, ONE MICROSOFT WAY, REDMOND WA 98052-6399
Cindy Kent director 7601 PENN AVENUE SOUTH, RICHFIELD MN 55418
Patricia L Wadors director C/O ALIGN TECHNOLOGY INC, 881 MARTIN AVE, SANTA CLARA CA 95050
Dawn G Lepore director 1425 BROADWAY PMB 41, SEATTLE WA 99122
Jeffrey D Jordan director 2865 SAND HILL ROAD #101, MENLO PARK CA 94025
Elizabeth G Nabel director BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115
Jeffrey S Brodsky director C/O MORGAN STANLEY 1585 BROADWAY, NEW YORK NY 10036
Thomas J Neff director SPENCER STUART & ASSOCIATES, 277 PARK AVE, NEW YORK NY 10172
William H. Frist director 600 MONTGOMERY STREET, SAN FRANCISCO CA 94111

Accolade (Accolade) Headlines

From GuruFocus

Accolade Inc CFO Stephen Barnes Sells 640 Shares

By GuruFocus Research GuruFocus Editor 05-25-2023

Accolade Inc CEO Rajeev Singh Sells 1,578 Shares

By GuruFocus Research GuruFocus Editor 05-25-2023

Accolade Inc CEO Rajeev Singh Sells 1,456 Shares

By GuruFocus Research 05-26-2023

Report: Employees are Overwhelmed, Delaying Care at High Rates

By PRNewswire PRNewswire 06-05-2023

Accolade to Announce Fiscal First Quarter 2024 Financial Results

By sperokesalga sperokesalga 06-13-2023